Peer-reviewed veterinary case report
Inflammation protein changes in dogs with bone cancer
By Axiak‐Bechtel, Sandra M. et al.·Published in Veterinary Medicine and Science·2019·Comparative Oncology Laboratory Department of Veterinary Medicine and Surgery College of Veterinary Medicine University of Missouri Columbia MO USA, United States·View original on Crossref →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Dogs with osteosarcoma have altered pro‐ and anti‐inflammatory cytokine profiles
- Species:
- dog
Plain-English summary
A group of dogs with osteosarcoma, a type of bone cancer, showed changes in their immune response compared to healthy dogs. Researchers measured certain immune markers in dogs receiving pain relief medication (NSAIDs) and those not receiving it. They found that dogs with osteosarcoma had higher levels of a specific immune marker (IL-6) but similar levels of others compared to healthy dogs. This suggests that the immune system in dogs with osteosarcoma reacts differently, regardless of whether they are on NSAIDs. More research is needed to understand how these changes could affect treatment and outcomes for these dogs.
People also search for: dog osteosarcoma treatment · dog cancer immune response · NSAIDs for dogs with cancer
Abstract
AbstractBackgroundCurrent advances in immunotherapy are an exciting area of study in canine osteosarcoma (OSA). The objective of this study was to determine the immune response in dogs with osteosarcoma by measuring stimulated leukocyte production of tumor necrosis factor (TNF), interleukin (IL)‐6, IL‐10 and TNF and IL‐6 to IL‐10 ratios.MethodsWhole blood was collected from dogs with osteosarcoma receiving non‐steroidal anti‐inflammatory drugs (NSAIDs, n = 11), dogs with osteosarcoma not receiving NSAIDs (n = 14) and healthy dogs (n = 5).ResultsNo difference in TNF production was found among healthy and OSA dogs regardless of NSAID administration following stimulation with lipopolysaccharide (LPS) (p = .410), lipoteichoic acid (LTA) (p = .693) or PBS (p = .120). Leukocyte IL‐6 production was greater in all dogs with OSA after stimulation with LPS (p = .015), LTA (p = .014) and PBS (p = .034) with no difference between OSA dogs receiving NSAIDs and those not. No differences in IL‐10 were found among healthy controls and dogs with OSA regardless of NSAID use. There was no difference among groups for LPS‐stimulated TNF to IL‐10 ratios (p = .407). For LTA‐stimulated leukocytes, the TNF to IL‐10 ratio was lower in dogs with OSA than in healthy dogs (p = .031) with no difference between OSA NSAID dogs compared to OSA non‐NSAID dogs (p = .059). No differences were found in LPS (p = .310)‐ or LTA (p = .265)‐stimulated leukocyte IL‐6 to IL‐10 production ratios among groups.ConclusionsDogs with osteosarcoma have an altered pro‐ and anti‐inflammatory immunologic profile compared to healthy dogs regardless of NSAID use. Further study is indicated to determine the potential prognostic and therapeutic implications of these findings.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Crossref: https://doi.org/10.1002/vms3.191